Kamada Ltd. — Report Publication Announcement 2016

Sep 1, 2016

_________ false

����� ��"�	2 380
KAMADA LTD
Corporation no: 511524605	10215
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	01/09/2016
	www.isa.gov.il			www.tase.co.il				Reference:	2016-02-116062	Time of broadcast: 13:33 13:32:22

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
KMDA_Files_BLA_for_IgG_Rabies_FINAL_01_09_16_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 26/07/2016
Address: Sapir 7 P.O.B 4081 , Ness-Ziona 74036   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: liatc@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: Livneh Nir Position of Signatory in the reporting corporation: Attorney/Legal Counsel Name of Employer Company:
Address: Sapir 7 , Ness-Ziona 74036 Telephone: 072-2748242 Facsimile: 072-2449318 E-mail: nirl@kamada.com 1